11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022
The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc22-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc22-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Transient increases in urine albumin excretion are reported with short-term hyperglycemia, exercise, urine tract infections, sustained blood pressure elevation, heart failure, fever, and hyperlipidemia (451).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [451]
In the citing paper
“The ADA/ EASD statement recommends that patients with T2D who have established ASCVD, CKD, or clinical heart failure be treated with an SGLT2i (or GLP-1 RA) with proven cardiovascular bene fi t as part of a glucose-lowering regimen independent of HbA1c, but with consideration of patient-speci fi c factors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [145]
In the citing paper
“Both the ADA and KDIGO recommend annual screening of patients with diabetes for CKD (17,18) (Fig. 1).”
In the citing paper
“This recommendation is based on strong evidence that SGLT2i reduce CKD progression, HF, and ASCVD risk in patients with T2D and CKD.”
In the citing paper
“These trials enrolled participants with albuminuria (ACR ≥300 mg/g and ≥200 mg/g, respectively); therefore, current evidence is strongest in this population, as emphasized by ADA recommendations (17) (Table 1).”
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023 · cited 1×
“Intensive glycemic control with the goal of achieving near-normoglycemia has been shown in large prospective randomized studies to delay the onset and progression of albuminuria and reduced eGFR in patients with type 1 diabetes (50,51) and type 2 diabetes (1,52 – 57).”
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Cited by
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Baigent, C., Emberson, J., Haynes, R., Herrington, W. G., Judge, P., Landray, M. J., Mayne, K. J., Ng, S. Y. A., Preiss, D., Roddick, A. J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02074-8 · Cited by 1,020
“…p t s 51) Although some clinical practice guidelines have started recommending use of SGLT2 inhibitors in type 2 diabetes at eGFRs down to 20 mL/min/1·73m 2 (based on grade B levels of evidence), (52, 53) many other recommendations limit initiation to those with eGFR above 25 or 30 mL/min/1·73m 2 .”
de Boer, I. H., Khunti, K., Sadusky, T., Tuttle, K. R., Neumiller, J. J., Rhee, C. M., Rosas, S. E., Rossing, P., & Bakris, G. (2022) · Diabetes Care · doi:10.2337/dci22-0027 · Cited by 919
Molecular mechanisms and therapeutic targets for diabetic kidney disease
Tuttle, K. R., Agarwal, R., Alpers, C. E., Bakris, G. L., Brosius, F. C., Kolkhof, P., & Uribarri, J. (2022) · Kidney International · doi:10.1016/j.kint.2022.05.012 · Cited by 668
Targeting inflammation to treat diabetic kidney disease: the road to 2030
Rayego-Mateos, S., Rodrigues-Diez, R. R., Fernandez-Fernandez, B., Mora-Fernández, C., Marchant, V., Donate-Correa, J., Navarro-González, J. F., Ortiz, A., & Ruiz-Ortega, M. (2023) · Kidney International · doi:10.1016/j.kint.2022.10.030 · Cited by 366
de Boer, I. H., Khunti, K., Sadusky, T., Tuttle, K. R., Neumiller, J. J., Rhee, C. M., Rosas, S. E., Rossing, P., & Bakris, G. (2022) · Kidney International · doi:10.1016/j.kint.2022.08.012 · Cited by 353
Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Diabetes Care · doi:10.2337/dci23-0036 · Cited by 351
Chen, L., Sun, S., Gao, Y., & Ran, X. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14840 · Cited by 260
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Di Martino, A., Albanese, G., Di Salvo, J., Epifani, R., Marfella, R., Docimo, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073651 · Cited by 256
Quattrin, T., Mastrandrea, L. D., & Walker, L. S. K. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00223-4 · Cited by 244
“158 The most common disorders include autoimmune thyroid disease (either hypo-thyroidism or hyperthyroidism), coeliac disease, and primary adrenal insufficiency.”
BackgroundGreen, J. B., Mottl, A. K., Bakris, G., Heerspink, H. J. L., Mann, J. F. E., McGill, J. B., Nangaku, M., Rossing, P., Scott, C., Gay, A., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac198 · Cited by 164
Sacks, D. B., Arnold, M. A., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad080 · Cited by 205
Kwan, T. W., Wong, S. S., Hong, Y., Kanaya, A. M., Khan, S. S., Hayman, L. L., Shah, S. H., Welty, F. K., Deedwania, P. C., Khaliq, A., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001145 · Cited by 133
Combination therapy for kidney disease in people with diabetes mellitus
van Raalte, D. H., Bjornstad, P., Cherney, D. Z. I., de Boer, I. H., Fioretto, P., Gordin, D., Persson, F., Rosas, S. E., Rossing, P., Schaub, J. A., et al. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00827-z · Cited by 127
Epstein, M., Kovesdy, C. P., Clase, C. M., Sood, M. M., & Pecoits‐Filho, R. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2022.04.016 · Cited by 134
Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Kelsey, M. D., Nelson, A. J., Green, J. B., Granger, C. B., Peterson, E. D., McGuire, D. K., & Pagidipati, N. J. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.046 · Cited by 106
Handelsman, Y., Butler, J., Bakris, G. L., DeFronzo, R. A., Fonarow, G. C., Green, J. B., Grunberger, G., Januzzi, J. L., Klein, S., Kushner, P. R., et al. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108389 · Cited by 119
Heerspink, H. J. L., Agarwal, R., Bakris, G. L., Cherney, D. Z. I., Lam, C. S. P., Neuen, B. L., Sarafidis, P. A., Tuttle, K. R., Wanner, C., BRINKER, M. D., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae132 · Cited by 110
Zhang, Y., Jiang, L., Wang, J., Wang, T., Chien, C., Huang, W., Fu, X., Xiao, Y., Fu, Q., Wang, S., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01676-5 · Cited by 96
Bakris, G. L., Ruilope, L. M., Anker, S. D., Filippatos, G. S., Pitt, B., Rossing, P. R., Fried, L. P., Roy‐Chaudhury, P., Sarafidis, P. A., Ahlers, C., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.08.040 · Cited by 102
Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
Lim, L.-L., Chow, E., & Chan, J. C. N. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00776-2 · Cited by 91
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Advances in the management of chronic kidney disease
Chen, T. K., Hoenig, M. P., Nitsch, D., & Grams, M. E. (2023) · BMJ · doi:10.1136/bmj-2022-074216 · Cited by 122
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 153
Tangri, N., Peach, E. J., Franzén, S., Barone, S., & Kushner, P. R. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02482-5 · Cited by 92
Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease
Nee, R. J., Yuan, C. M., Narva, A. S., Yan, G., & Norris, K. C. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac283 · Cited by 94
Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus
Yu, J., Lee, S.-H., & Kim, M. K. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.105 · Cited by 65
Prognostic Nutritional Index as a Predictor of Diabetic Nephropathy Progression
Zhang, J., Xiao, X., Wu, Y., Yang, J., Zou, Y., Zhao, Y., Yang, Q., & Liu, F. (2022) · Nutrients · doi:10.3390/nu14173634 · Cited by 68
“4 g/kg/day) [28], is recommended to slow the renal function decline, but less than the level is not allowed [29].”
BackgroundSarafidis, P. A., Agarwal, R., Pitt, B., Wanner, C., Filippatos, G. S., Boletis, J., Tuttle, K. R., Ruilope, L. M., Rossing, P. R., Toto, R., et al. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000149 · Cited by 64
Yang, Q., Lang, Y., Yang, W., Yang, F., Yang, J., Wu, Y., Xiao, X., Qin, C., Zou, Y., Zhao, Y., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110592 · Cited by 64
van Heck, J. I. P., Gaćeša, R., Stienstra, R., Fu, J., Zhernakova, A., Harmsen, H. J. M., Weersma, R. K., Joosten, L. A. B., & Tack, C. J. (2022) · Diabetes Care · doi:10.2337/dc21-2225 · Cited by 62
Alcocer, L. A., Bryce, A., Brasil, D., Lara-Terán, J. J., Cortes, J. M., Quesada, D., & Rodriguez, P. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00605-5 · Cited by 71
“In contrast to other cardiovascular comorbidities, most guidelines for the management of patients with T2D recommend ACEis or ARBs as first-line treatment for hypertension, with no preference for one RAASi over another, including those from the American Diabetes Association [98] and LASH [21].”
ResultIntegrating CKD Into US Primary Care: Bridging the Knowledge and Implementation Gaps
Vassalotti, J. A., & Boucree, S. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.01.1066 · Cited by 64
Lamprea-Montealegre, J. A., Madden, E., Tummalapalli, S. L., Chu, C. D., Peralta, C. A., Du, Y., Singh, R., Kong, S. X., Tuot, D. S., Shlipak, M. G., et al. (2022) · Diabetes Care · doi:10.2337/dc22-0614 · Cited by 52
Chen, M., Fang, Y., Ge, Y., Qiu, S., Dworkin, L. D., & Gong, R. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103127 · Cited by 52
“Clinical managements of DKD remain a challenge, especially for patients at high risk of progression [9].”
BackgroundBeernink, J. M., van Mil, D., Laverman, G. D., Heerspink, H. J. L., & Gansevoort, R. T. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16359 · Cited by 58
Yen, F., Wei, J. C., Shih, Y., Hsu, C., & Hwu, C. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01821-8 · Cited by 51
Rossing, P. R., Agarwal, R., Anker, S. D., Filippatos, G. S., Pitt, B., Ruilope, L. M., Fonseca, V. A., Umpierrez, G. E., Caramori, M. L., Joseph, A., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14883 · Cited by 50
Luo, X., Xu, J., Zhou, S., Xue, C., Chen, Z., & Mao, Z. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000205 · Cited by 45
Urine Albumin Measurements in Clinical Diagnostics
Seegmiller, J. C., & Bachmann, L. M. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvad174 · Cited by 61
Screening for chronic kidney disease: change of perspective and novel developments
van Mil, D., Kieneker, L. M., Heerspink, H. J. L., & Gansevoort, R. T. (2024) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001016 · Cited by 55
Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKD
Hu, J.-C., Shao, S., Tsai, D. H., Chuang, A. T.-M., Liu, K., & Lai, E. C. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.0946 · Cited by 48
Alicic, R. Z., & Nicholas, S. B. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.05.003 · Cited by 48
Sacchetta, L., Chiriacò, M., Nesti, L., Leonetti, S., Forotti, G., Natali, A., Solini, A., & Tricò, D. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01675-6 · Cited by 47
Finerenone in diabetic kidney disease: A systematic review and critical appraisal
Singh, A. K., Singh, A., Singh, R., & Misra, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102638 · Cited by 43
Wexler, D. J., de Boer, I. H., Ghosh, A., Younes, N., Bebu, I., Inzucchi, S. E., McGill, J. B., Mudaliar, S., Schade, D., Steffes, M. W., et al. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.1487 · Cited by 39
von Scholten, B. J., Kreiner, F. F., Rasmussen, S., Rossing, P. R., & Idorn, T. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221112490 · Cited by 46
Nabrdalik, K., Kwiendacz, H., Moos, J., Moos, Ł., Kulpa, J., Brzoza, Z., Stompór, T. P., Gumprecht, J., & Lip, G. Y. H. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101726 · Cited by 48
Liew, A., Lydia, A., Matawaran, B. J., Susantitaphong, P., Tran, H. T. B., & Lim, L. (2023) · Nephrology · doi:10.1111/nep.14167 · Cited by 42
Cohen, J. B., Bancos, I., Brown, J. M., Sarathy, H., Turcu, A. F., & Cohen, D. L. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-100438 · Cited by 38
Agarwal, R., Pitt, B., Rossing, P. R., Anker, S. D., Filippatos, G. S., Ruilope, L. M., Kovesdy, C. P., Tuttle, K. R., Vaduganathan, M., Wanner, C., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.1505 · Cited by 36
Schallmoser, S., Züger, T., Kraus, M., Saar‐Tsechansky, M., Stettler, C., & Feuerriegel, S. (2023) · Journal of Medical Internet Research · doi:10.2196/42181 · Cited by 42
“We considered an individual to have developed nephropathy if 1 measurement of eGFR 60 ml/minute per 1.73 m 2 or 2 measurements of the ratio of albumin to creatinine in the urine ≥ 30 mg/g were recorded [23].”
InfluentialJi, J., Shi, H., Li, Z.-L., Jin, R., Qu, G., Zheng, H., Wang, E., Qiao, Y., Li, X., Ding, L., et al. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01140-4 · Cited by 35
“Inclusion criteria: Eligible patients with DN, had a history of DM and urinary albumin/creatinine ratio ≥ 300 mg/g, as well as an estimated glomerular fi ltration rate ≤ 60 mL·min − 1 (1.73 m 2 ) − 1 [25].”
BackgroundInfluentialMentz, R. J., Brunton, S., & Rangaswami, J. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02023-y · Cited by 41
“…HR: 0.86 [95% CI 0.78–0.95]; p = 0.0018) and 23% reduction in risk of the composite kidney outcome (consisting of sustained ≥ 57% decrease in eGFR from baseline over ≥ 4 weeks or renal death) for finerenone vs. placebo (5.5% vs. 7.1%; HR: 0.77 [95% CI 0.67– 0.88]; p = 0.0002) [96, 100].”
BackgroundMethodInfluentialUse of Glucose-Lowering Agents in Diabetes and CKD
Alicic, R. Z., Neumiller, J. J., Galindo, R. J., & Tuttle, K. R. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.09.018 · Cited by 38
Tang, M., Berg, A. H., Rhee, E. P., Allegretti, A. S., Nigwekar, S. U., Karumanchi, S. A., Lash, J. P., & Kalim, S. (2022) · Diabetes Care · doi:10.2337/dc22-1399 · Cited by 34
Zhao, J. Z., Weinhandl, E. D., Carlson, A. M., & St. Peter, W. L. (2023) · Kidney Medicine · doi:10.1016/j.xkme.2022.100564 · Cited by 34
Fu, E. L., D’Andrea, E., Wexler, D. J., Patorno, E., & Paik, J. M. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000115 · Cited by 40
Risk-based versus GFR threshold criteria for nephrology referral in chronic kidney disease
Oliva-Dámaso, N., Delanaye, P., Oliva-Dámaso, E., Payán, J., & Glassock, R. J. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac104 · Cited by 36
King, A., & Miller, E. M. (2022) · Clinical Diabetes · doi:10.2337/cd22-0027 · Cited by 34
Elkhalifa, A. M. E., Nazar, M., Ali, S. I., Khursheed, I., Taifa, S., Ahmad Mir, M., Shah, I. H., Malik, M., Ramzan, Z., Ahad, S., et al. (2024) · Life · doi:10.3390/life14010099 · Cited by 31
Crosstalk of Hyperglycaemia and Cellular Mechanisms in the Pathogenesis of Diabetic Kidney Disease
Efiong, E. E., Bazireh, H., Fuchs, M., Amadi, P. U., Effa, E., Sharma, S., & Schmaderer, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252010882 · Cited by 33
“It is a significant risk factor for the initiation and development of DKD [36,38,54].”
BackgroundAkiyama, H., Nishimura, A., Morita, N., & Yajima, T. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1111984 · Cited by 32
SGLT2 Inhibitors in the Treatment of Diabetic Kidney Disease: More than Just Glucose Regulation
Klen, J., & Dolžan, V. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071995 · Cited by 38
Kelly, M., Lewis, J., Rao, H., Carter, J., Portillo, I., & Beuttler, R. (2022) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2737 · Cited by 29
AACC/NKF Guidance Document on Improving Equity in Chronic Kidney Disease Care
Pierre, C. C., Marzinke, M. A., Ahmed, S. B., Collister, D., Colón-Franco, J. M., Hoenig, M. P., Lorey, T. S., Palevsky, P. M., Palmer, O. M. P., Rosas, S. E., et al. (2023) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfad022 · Cited by 32
Shi, L., Xue, Y., Yu, X., Wang, Y., Hong, T., Li, X., Ma, J., Zhu, D., & Mu, Y. (2024) · JMIR Public Health and Surveillance · doi:10.2196/54429 · Cited by 37
Cao, H., Liu, T., Wang, L., & Ji, Q. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14702 · Cited by 33
The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
Koutentakis, M., Kuciński, J., Świeczkowski, D., Surma, S., Filipiak, K. J., & Gąsecka, A. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10110465 · Cited by 38
“The current ADA guidelines recommend canagliflozin, empagliflozin, or dapagliflozin in T2DM patients with DKD to slow the course of renal disease and cardiovascular events (estimated GFR of 25 mL/min/1.73 m 2 , and urinary albumin creatinine ≥ 300 mg/g) [197].”
BackgroundInfluentialHabte‐Asres, H. H., Murrells, T., Nitsch, D., Wheeler, D. C., & Forbes, A. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110117 · Cited by 34
“There are national and international guidelines on diabetes management for patients with CKD that advocate a bi-annual screening review of CKD status in people with diabetes [10 – 12].”
BackgroundInfluentialMeasuring Albuminuria in Individuals With Obesity: Pitfalls of the Urinary Albumin-Creatinine Ratio
Chagnac, A., & Friedman, A. N. (2024) · Kidney Medicine · doi:10.1016/j.xkme.2024.100804 · Cited by 35
Hsieh, M.-H., Chen, Y., Ho, C.-H., & Lin, C. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s369552 · Cited by 29
Management of diabetic kidney disease: where do we stand?: A narrative review
Sindhu, D., Sharma, G. S., & Kumbala, D. R. (2023) · Medicine · doi:10.1097/md.0000000000033366 · Cited by 31
Besci, Ö., Foss‐Freitas, M. C., Guidorizzi, N. R., Güler, M. Ç., Gilio, D., Maung, J. N., Schill, R. L., Hoose, K. S., Obua, B. N., GOMES, A. D., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad606 · Cited by 28
Rabbani, N., Adaikalakoteswari, A., Larkin, J. R., Panagiotopoulos, S., MacIsaac, R. J., Yue, D. K., Fulcher, G. R., Roberts, M. A., Thomas, M. C., Ekinci, E. I., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010152 · Cited by 26
Haq, K., & Patel, D. M. (2023) · Medical Clinics of North America · doi:10.1016/j.mcna.2023.03.002 · Cited by 28
Rossing, P. R. (2022) · Kidney International Supplements · doi:10.1016/j.kisu.2021.11.005 · Cited by 25
Shen, Y., Xie, L., Chen, X., Mao, L., Qin, Y., Lan, R., Yang, S., Hu, J., Li, X., Ye, H., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.995028 · Cited by 27
Clinical implications and guidelines for CKD in type 2 diabetes
Zhang, R. M., Persson, F., McGill, J. B., & Rossing, P. R. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac285 · Cited by 27
Chen, L., Zhu, Z., Ye, S., & Zheng, M. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s387426 · Cited by 26
Therapeutic Advances in Diabetic Kidney Disease
Georgianos, P. I., Vaios, V., Eleftheriadis, T., Papachristou, E. C., & Liakopoulos, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032803 · Cited by 26
“Abbreviations: CKD, chronic kidney disease; CI, confidence interval; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HF, heart failure; HR, hazard ratio; RAS, renin angiotensin system; T2D, Type 2 diabetes; UACR, urinary albumin to creatinine ratio.”
BackgroundInfluentialTang, Y., Ang, L. P., Jaiswal, M., Dillon, B. R., Esfandiari, N. H., Shah, H., Spino, C., Plunkett, C., Perkins, B. A., Pop‐Busui, R., et al. (2023) · Diabetes · doi:10.2337/db23-0247 · Cited by 25
Xia, C., Han, Y., Yin, C., Geng, R., Liu, Z., Du, Y., & Yu, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1220516 · Cited by 26
Chen, W., Zheng, L., Wang, J., Lin, Y., & Zhou, T. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1320603 · Cited by 27
“Recently published guidelines from the American Diabetes Association (ADA) (111 – 113), the American Association of Clinical Endocrinology (AACE) (114) and the updated Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group (112, 115) recommend the addition of the oral NS-MRAs FIN to…”
BackgroundNicholas, S. B., Correa‐Rotter, R., Desai, N. R., Guo, L., Navaneethan, S. D., Pantalone, K. M., Wanner, C., Hamacher, S., Fatoba, S., Horvat-Broecker, A., et al. (2024) · Journal of Nephrology · doi:10.1007/s40620-024-02070-y · Cited by 28
“Treatment guidelines recommend UACR should be reduced by ≥ 30% in patients with CKD and UACR ≥ 300 mg/g [20].”
InfluentialNavaneethan, S. D., Anker, S. D., Filippatos, G. S., Pitt, B., Rossing, P. R., Ruilope, L. M., August, P., BRINKER, M. D., Lage, A. Z., Roberts, L., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.03.018 · Cited by 25
Efficacy and Safety of Low-dose Spironolactone for Chronic Kidney Disease in Type 2 Diabetes
Oiwa, A., Hiwatashi, D., Takeda, T., Miyamoto, T., Kawata, I., Koinuma, M., Yamazaki, M., & Komatsu, M. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad144 · Cited by 25
Liu, Y., An, C., Liu, P., Yang, F., & Zhao, Q. (2023) · Renal Failure · doi:10.1080/0886022x.2023.2217287 · Cited by 27
Fluorescent nanomaterials for the detection of chronic kidney disease
Bhatt, P., Kukkar, D., & Kim, K. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117572 · Cited by 22
Guo, J., Liu, C., Wang, Y., Shao, B., Fong, T. L., Lau, N. C., Zhang, H., Li, H.-D., Wang, J., Lu, X., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102482 · Cited by 24
“23 For the risk of the DKD onset, the selection data consistent with the diagnosis of DKD, 24 including directly reported the risk of DKD onset, Alb presence (urinary albumin to creatinine ratio ≥ 30 mg/g), or eGFR decline ( 60 ml/ min/1.73 m 2 ).”
BackgroundInfluentialFan, R., Kong, J., Zhang, J., & Zhu, L. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1471642 · Cited by 28
Salehidoost, R., Boroujeni, G. T., Feizi, A., Aminorroaya, A., & Amini, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-20277-6 · Cited by 26
Kushner, P. R., Cavender, M. A., & Mende, C. W. (2022) · Clinical Diabetes · doi:10.2337/cd21-0119 · Cited by 29
Re-understanding and focusing on normoalbuminuric diabetic kidney disease
An, N., Wu, B., Yang, Y., Huang, Z.-H., & Feng, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1077929 · Cited by 27
Caring for Patients With Diabetes in Stroke Neurology
Kernan, W. N., Forman, R., & Inzucchi, S. E. (2022) · Stroke · doi:10.1161/strokeaha.122.038163 · Cited by 26
Morales, J., Dagogo-Jack, S. E., Fonseca, V. A., Neumiller, J. J., & Rosas, S. E. (2023) · Clinical Diabetes · doi:10.2337/cd22-0110 · Cited by 22
Zeng, C. C., Liu, M., Zhang, Y., Deng, S., Xin, Y., & Hu, X. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad645 · Cited by 30
Emerging role of antidiabetic drugs in cardiorenal protection
Fu, W.-J., Huo, J., Mao, Z., Pan, S.-K., Liu, D., Liu, Z., Wu, P., & Gao, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1349069 · Cited by 24
A new perspective on proteinuria and drug therapy for diabetic kidney disease
Zhang, R., Wang, Q., Li, Y., Li, Q., Zhou, X., Chen, X., & Dong, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1349022 · Cited by 25
Cost and utilization of healthcare services for persons with diabetes
Reynolds, E. L., Mizokami‐Stout, K., Putnam, N. M., Banerjee, M., Albright, D. K., Ang, L. P., Lee, J. M., Pop‐Busui, R., Feldman, E. L., & Callaghan, B. C. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110983 · Cited by 25
Metadata
- Authors
- American Diabetes Association Professional Practice Committee
- Corresponding author
- American Diabetes Association Professional Practice Committee
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2021-12-16
- Volume
- 45
- Issue
- Supplement_1
- Pages
- S175-S184
- ISSN
- 0149-5992 (ISSN-L)
- OpenAlex
- W4200340161
- Semantic Scholar
- 40f2cfa2d0038ac9f80bb94b8f8217ad1566bd6e
- Cited by
- 344
- References
- 112
- Citations by year
- 2026: 15 · 2025: 38 · 2024: 66 · 2023: 123 · 2022: 101 · 2021: 1
- FWCI
- 11.91
- Type
- journal article
- Language
- en
- Update notices
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- chronic kidney disease, diabetes mellitus, risk management, clinical guidelines, quality of care
- MeSH terms
- Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Renal Insufficiency, Chronic, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.